OSE Immunotherapeutics SA
PAR:OSE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
OSE Immunotherapeutics SA
Common Shares Outstanding
OSE Immunotherapeutics SA
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Common Shares Outstanding
€22.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Valneva SE
PAR:VLA
|
Common Shares Outstanding
€173.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Common Shares Outstanding
€50m
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Inventiva SA
PAR:IVA
|
Common Shares Outstanding
€193.2m
|
CAGR 3-Years
66%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Common Shares Outstanding
$235.6m
|
CAGR 3-Years
36%
|
CAGR 5-Years
34%
|
CAGR 10-Years
26%
|
|
|
Abivax SA
PAR:ABVX
|
Common Shares Outstanding
€78.5m
|
CAGR 3-Years
52%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Common Shares Outstanding?
Common Shares Outstanding
22.4m
EUR
Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Common Shares Outstanding amounts to 22.4m EUR.
What is OSE Immunotherapeutics SA's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
8%
Over the last year, the Common Shares Outstanding growth was 2%. The average annual Common Shares Outstanding growth rates for OSE Immunotherapeutics SA have been 7% over the past three years , 8% over the past five years , and 8% over the past ten years .
